Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardinal Health Inc.'s shares CAH, -0.84% fell 1.2% premarket on Thursday after the company reported mixed results for its fiscal third quarter but raised its full-year profit outlook. The drug distributor and lab-equipment provider reported net income of $258 million, or $1.05 per share, down from $345 million, or $1.34 per share, in the year-earlier period.

Cardinal Health's stock falls on mixed quarterly results

Revenue increased 9% to $54.9 billion GAAP1 operating earnings were $367 million; GAAP diluted EPS was $1.05 Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08 Fiscal year 2024 non-GAAP EPS guidance 2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35 Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50 DUBLIN, Ohio , May 2, 2024  /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of fiscal year 2023. Third quarter GAAP operating earnings were $367 million and GAAP diluted earnings per share (EPS) were $1.05, which included a non-cash, pre-tax goodwill impairment of $90 million related to the Global Medical Products and Distribution (GMPD) segment as a result of the reallocation of goodwill related to the reporting structure update.

Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance

Manulife Financial

Toyota Motor

Investing for retirement can be one of the most essential steps to securing a future of overall financial stability. Nowadays, many investors need to start preparing a nest egg at a young age despite the idea of retirement seeming unnecessary.

Shhh! 3 Secret Retirement Stocks Flying Below Wall Street's Radar

Cardinal Health's (CAH) third-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.

What's in Store for Cardinal Health (CAH) in Q3 Earnings?

Besides Wall Street's top -and-bottom-line estimates for Cardinal (CAH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Seeking Clues to Cardinal (CAH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Apple

Alerus Financial Corp

CNO Financial Group

Chesapeake Utilities

Expeditors International of Washington

FactSet Research Systems

Leggett & Platt

MSA Safety

Northrop Grumman

Pool

Tetra Tech

Eleven long-term dividend growth companies announced their annual dividend increases in the second half of April. Investors were rewarded with 10%+ increases from Grainger and Parker-Hannifin.

Apple, Cardinal Health Among 12 Companies To Announce Dividend Increases In First Half Of May

Hologic

10X Genomics

Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.

3 Medical Products Stocks Set to Beat This Earnings Season

The U.S. Food and Drug Administration on Thursday sent a warning letter to Cardinal Health after an inspection of its facility in Illinois showed that the company was marketing unapproved devices.

US FDA sends warning to Cardinal Health for marketing unapproved devices

Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth

Colgate-Palmolive

Dollar General

Flowers Foods

Huntington Ingalls Industries

McDonald's

Otis Worldwide

Are we headed for a repeat of 2022's brutal selloff? While no one can predict the future with certainty, current market trends are raising some ominous red flags.

A Repeat of 2022? 7 Defensive Stocks to Buy Before the Correction.

Cardinal Health (CAH) closed the most recent trading day at $103.37, moving +0.53% from the previous trading session.

Cardinal Health (CAH) Increases Yet Falls Behind Market: What Investors Need to Know

Recently, Zacks.com users have been paying close attention to Cardinal (CAH). This makes it worthwhile to examine what the stock has in store.

Is Trending Stock Cardinal Health, Inc. (CAH) a Buy Now?

Cigna

McKesson

Healthcare stocks, especially industry leaders that offer a wide range of products and services, can be an investor's best friend due to the growing need for increased development of healthcare products and services. These stocks tend to provide investors with a substantial return on their investment.

The Top 3 Healthcare Stocks to Buy in April 2024

The pharmaceutical distribution contract with OptumRx will expire in June.

Cardinal Health Won't Renew OptumRx Distribution Pact. Guidance Is Unchanged.

UnitedHealth Group

Cardinal Health said on Monday its pharma distribution contracts with UnitedHealth Group Inc's OptumRx unit will not be renewed after they expire at the end of June.

Cardinal Health says contracts with UnitedHealth's OptumRx will not be renewed

Cardinal Health Inc. ‘s stock CAH, +2.07% fell 3.6% early Monday, after the pharmaceuticals distributor and medical lab products maker said its contracts with pharmacy benefits manager OptumRx will expire at the end of June and will not be renewed. The Dublin, Ohio-based company said it still expects 2024 EPS of $7.20 to $7.35 despite the end of the contract, which generated 16% of its revenue in fiscal 2023.

Cardinal Health's stock slides 3.6% after announcing contract with OptumRx will not be renewed after end-June

DUBLIN, Ohio , April 22, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35.

Cardinal Health Reaffirms Fiscal 2024 non-GAAP EPS Guidance and Long-term Targets Amidst Nonrenewal of OptumRx Customer Contracts

Cardinal Health is overvalued, with a dividend yield lower than its historical average and a high P/E ratio. Growth projections for the Company are moderate, with a projected growth rate of 7.8% for the next 5 years. Return projections using the discounted dividend model suggest that CAH is still overvalued, with a fair price of around $79 compared to its current price of $106.

Cardinal Health: Solid Business But Overvalued

In the latest trading session, Cardinal Health (CAH) closed at $107.03, marking a +1.84% move from the previous day.

Cardinal Health (CAH) Increases Despite Market Slip: Here's What You Need to Know

Forestar Group

Blue Owl Capital Corp

CPI, the Consumer Price Index, is a metric used to gauge the rate of inflation and deflation. It's released by the Bureau of Labor Statistics (BLS) and reports the monthly fluctuations in consumer goods and services prices.

CPI Shock Waves: 3 Undervalued Stocks to Ride the Volatility

Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Cardinal Health, Inc. (CAH) is Attracting Investor Attention: Here is What You Should Know

Baxter

Fresenius Medical Care

Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

Ares Capital

Strong buy companies are a great place to start when seeking companies to invest in. It can require a fair amount of effort and research to find stocks that are also trading at a bargain rate.

Wall Street Favorites: 3 Bargain Stocks With Strong Buy Ratings for April 2024

Cardinal Health (CAH) concluded the recent trading session at $109.47, signifying a -0.41% move from its prior day's close.

Here's Why Cardinal Health (CAH) Fell More Than Broader Market

Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

News for Cardinal Health Stock (CAH)